Tagged with R

Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation.   If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…

UAE With a combined experience of over five decades in the pharmaceutical industry including senior executive roles at companies such as Merck and Janssen, Karim Smaira and Kamel Ghammachi have come a long way with Genpharm, the Dubai-based market access company they founded in 2012. After years of learning the ins…

Czech Republic Paul-François Cossa, country chair of Sanofi Czech Republic & Slovakia and General Manager CHC, reviews the outstanding performance of the company in 2019, breaks down his new vision for Sanofi in the Czech Republic and Slovakia after the divestment of Zentiva at the end of 2018, and explains how it…

Romania Iulia Arif-Percă executive director of the Local American Working Group (LAWG), shares her insights on the launched initiatives to finding new funding alternatives that will increase Romanian patients’ access to innovative medicines. She highlights the constraining environment in which innovative companies operate in, and how LAWG’s work contributes to the…

Belgium Belgian Former Minister of Social Affairs, Public Health and Asylum & Migration Maggie de Block outlines some of the key reforms her Ministry has rolled out since she took office in 2014 and the urgent changes to Belgian healthcare that still need to take place.   Along with the Netherlands,…

Romania Dan Zaharescu, executive director of the Romanian Association of Pharmaceutical Manufacturers (ARPIM), shares his insights on market access, the need to reform pricing methodologies, the debate around the claw-back tax, his expectations for the newly appointed minister of health and prime minister, as well as his objectives for 2020.  …

Global In an exclusive and wide-ranging interview, Tom O’Leary, chief information officer (CIO) of leading contract research organisation (CRO), ICON, highlights how data is already revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes. O’Leary also…

Romania László Attila, president of the Committee of Public Health of Romania, highlights the Committee’s efforts to mitigate the detrimental effects of Romania’s looming demographic crisis and medical “brain-drain”. Furthermore, he evaluates the country’s success in increasing the healthcare budget and emphasizes the importance of stable legislation.   Romania has the…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Opinion Francois Sandre, Head of Asia & JPAC for Sanofi Pasteur outlines the importance of a sustainable global vaccine ecosystem and why a value-based approach, ensuring a steady supply of vaccines, and encouraging innovation are all crucial to meeting the public health goals of the future.   Vaccination is one of…

Opinion Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of the crisis and responses to it will be.   The latest disruptor to global health and the economy is the…

Belgium On 3 February 2020 the Act of 20 December 2019 amending various legal provisions concerning shortages of medicinal products was published in the Official Gazette. Except for Articles 2 and 4, which entered into force on 31 January 2020, the act’s provisions entered into force on 13 February 2020. In our view, the…